BEXAGLIFLOZIN DIPROLINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H29ClO7.2C5H9NO2
Molecular Weight	695.197
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]2CCCN2.OC[C@H]3O[C@H]([C@H](O)[C@@H](O)[C@@H]3O)C4=CC(CC5=CC=C(OCCOC6CC6)C=C5)=C(Cl)C=C4

InChI

InChIKey=DAQOCDWUCJBXEI-GUJHQGHLSA-N

InChI=1S/C24H29ClO7.2C5H9NO2/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18;2*7-5(8)4-2-1-3-6-4/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2;2*4,6H,1-3H2,(H,7,8)/t20-,21-,22+,23-,24+;2*4-/m100/s1

HIDE SMILES / InChI

Description
Sources: http://www.theracos.com/sglt2-inhibitors/ | https://www.ncbi.nlm.nih.gov/pubmed/21215314

Bexagliflozin, also known as EGT1442, is a potent and selective SGLT2 inhibitor. Bexagliflozin is under investigation for the treatment of Type 2 Diabetes Mellitus. Bexagliflozin has been investigated for the treatment of Diabetes Mellitus and Type2 Diabetes Mellitus. Clinical studies have established that bexagliflozin significantly reduces blood glucose and glycated hemoglobin in subjects with diabetes. Treatment with bexagliflozin also induces weight loss and a reduction in systolic and diastolic blood pressure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/glucose cotransporter 2 25 Target ID: CHEMBL3884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21215314 \| http://www.theracos.com/sglt2-inhibitors/	Inhibitor 8297		2.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 259 Sources: http://adisinsight.springer.com/drugs/800035524 https://clinicaltrials.gov/ct2/show/NCT02836873	Primary		Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
692 ng × eq/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2604 ng × eq × h/g EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31432741	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		BEXAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	UGT2B7 389 UGT1A1 418 CYP2C19 991 CYP2C8 693 UGT1A9 380 UGT1A4 347 UGT1A6 307 CYP1A2 1054 CYP2B6 664 UGT1A10 291

Drug as victim

Target	Modality	Activity
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/ \| https://pubmed.ncbi.nlm.nih.gov/31432741/	major
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	minor
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	minor
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A10 291	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	no
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	yes
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31432741/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34372	https://www.001chemical.com/chem/search?q=DY34372
001 Chemical	DY34374	https://www.001chemical.com/chem/search?q=DY34374
1PlusChem LLC	1P008U59	https://www.1pchem.com/search?query=1P008U59
AstaTech	C71393	http://astatechinc.com/CPSResult.php?CRNO=C71393
BLD Pharm	BD629906	http://www.bldpharm.com/search/Search.html?keyword=BD629906
BioSynth	J-500393	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-500393
Cayman Chemical	21359	http://www.caymanchem.com/app/template/Product.vm/catalog/21359
Chem Scene	CS-5702	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5702
ChemShuttle	138999	https://www.chemshuttle.com/catalogsearch/result/?q=138999
KeyOrganics	AS-55919	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55919
MedChem Express	HY-17604	https://www.medchemexpress.com/search.html?q=HY-17604&ft=&fa=&fp=
MolPort	MolPort-044-561-857	https://www.molport.com/shop/molecule-link/MolPort-044-561-857
Molcore	MC34372	http://www.molcore.com/CatMC34372.html
Molcore	MC34374	http://www.molcore.com/CatMC34374.html
Molnova	M10426	https://www.molnova.com/en/serch-list.html?keywords=M10426
ShangHai Biochempartner	BCP000523	http://www.biochempartner.com/search_BCP000523
TargetMol	T7217	https://www.targetmol.com/search?keyword=T7217
Toronto Research Chemicals	B336785	https://www.trc-canada.com/product-detail/?CatNum=B336785
eMolecules	43473247	https://orderbb.emolecules.com/search/#?query=43473247
eMolecules	44786206	https://orderbb.emolecules.com/search/#?query=44786206
eMolecules	89940547	https://orderbb.emolecules.com/search/#?query=89940547
mcule	MCULE-8046541096	https://mcule.com/MCULE-8046541096/
mcule	MCULE-9598278085	https://mcule.com/MCULE-9598278085/

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Each subject with Type 2 Diabetes Mellitus will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.

Route of Administration: Oral

In Vitro Use Guide

Bexagliflozin (EGT1442) inhibited SGLT1 and SGLT2-mediated sodium-dependent AMG uptake in a dose-dependent manner. EGT1442 exhibited an IC50 of 2 nM with a 2435-fold selectivity ratio against SGLT2 compared to SGLT1.

Name

Type

Language

BEXAGLIFLOZIN DIPROLINE

Common Name

English

EGT-0001442 DIPROLINE

Code

English

EGT-1442 DIPROLINE

Code

English

L-PROLINE, COMPD. WITH (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(2-(CYCLOPROPYLOXY)ETHOXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL (2:1)

Systematic Name

English

Bexagliflozin diproline [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

44631917

Created by admin on Sat Dec 16 09:14:59 GMT 2023 , Edited by admin on Sat Dec 16 09:14:59 GMT 2023

PRIMARY

CAS

1118567-48-8

Created by admin on Sat Dec 16 09:14:59 GMT 2023 , Edited by admin on Sat Dec 16 09:14:59 GMT 2023

PRIMARY

FDA UNII

73J587R71C

Created by admin on Sat Dec 16 09:14:59 GMT 2023 , Edited by admin on Sat Dec 16 09:14:59 GMT 2023

PRIMARY

ACTIVE MOIETY


					EY00JF42FV

BEXAGLIFLOZIN

SUBSTANCE RECORD


					73J587R71C

BEXAGLIFLOZIN DIPROLINE

Details

SMILES

InChI

DescriptionSources: http://www.theracos.com/sglt2-inhibitors/ | https://www.ncbi.nlm.nih.gov/pubmed/21215314

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.theracos.com/sglt2-inhibitors/ | https://www.ncbi.nlm.nih.gov/pubmed/21215314

C_max

T_1/2